Pernix Therapeutics Surges 42% After Patent Case Win Against Generic From Actavis Labs

By Emma Court Markets MarketWatch Pulse

Pernix Therapeutics Holdings Inc. shares surged 42% in morning trade Thursday after the company said a district judge had ruled in its favor in a patent infringement case against Actavis Laboratories, which is part of Allergan PLC . The judge said Actavis could not make or sell a generic of Pernix's Zohydro ER, an opioid pain medication, until two patents expire in 2019 and 2034. Pernix Therapeutics shares have risen 17.2% over the last three months, compared with a 7.4% rise in the S&P 500 .

Continue Reading Below

Copyright © 2017 MarketWatch, Inc.